
Opinion|Videos|August 22, 2023
Overview of Abiraterone Options for Patients with Prostate Cancer
Author(s)Benjamin H. Lowentritt, MD, FACS
Benjamin H. Lowentritt, MD, FACS, shares background information on micronized abiraterone and discusses its role in the evolving prostate cancer treatment landscape.
Advertisement
Episodes in this series

Now Playing
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5














